Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
RYTHMOL SR (propafenone) is an extended-release oral antiarrhythmic agent approved in 2003 for the treatment of cardiac arrhythmias. It belongs to the class IC antiarrhythmic category and works by blocking sodium channels to restore normal heart rhythm. The drug is indicated for patients with various forms of atrial and ventricular arrhythmias requiring maintenance therapy.
With LOE approaching and competitive pressure at 30%, the brand team is likely in defense/optimization mode with smaller commercial footprint than growth-stage products.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
Working on RYTHMOL SR offers experience managing a mature cardiac therapeutic in a competitive market with emerging generic pressure. This role emphasizes brand defense, customer relationship management, and commercial optimization rather than market expansion—valuable experience for portfolio management and crisis mitigation roles.
Worked on RYTHMOL SR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.